Thus, an NFκB inhibitor BAY11-7082 was used to determine whether NFκB signaling in VSMCs would contribute to NLRP3 inflammasome activation and phenotypic transformation in hypertension. This evidence concerns the gene NFKB1 and hypertensive disorder.